Major Announcement on WHO ECDD on Kratom Decision

From the AKA:

WHO ECDD RECOMMENDS AGAINST CRITICAL REVIEW

The American Kratom Association has received initial reports from the World Health Organization Executive Committee on Drug Dependency’s report from the October meeting and they stated:

“The Committee concluded that there is insufficient evidence to recommend a critical review of kratom.”

This is an enormous validation of the comments you submitted and science we presented to the WHO ECDD. Your comments and ongoing scientific research seem to have weighed heavily in the decision.

The report stated “People report using kratom to self-medicate a variety of disorders and conditions, including pain, opioid withdrawal, opioid use disorder, anxiety and depression. Kratom is being used as a part of traditional medicine in some countries. Research is ongoing to determine the basic pharmacology and the potential therapeutic value of kratom, mitragynine and 7-hydroxymitragynine.”

Our fight is far from over in America as we still have state bans, import alerts, and an FDA that seems to ignore the science. However we cannot overstate how important avoiding a WHO critical review or outright scheduling is for millions of American kratom consumers!

The AKA’s Mac Haddow issued a video statement about the announcement that can be seen here.

WATCH AKA’s STATEMENT

WHO ECDD Recommends WHO Secretariat “Surveillance”

Although there was a not a full critical review recommendation, kratom and its chemical components are still going to be monitored by the WHO.

Their official statement: “Recommendation: The Committee recommended that kratom, mitragynine and 7-hydroxymitragynine be kept under surveillance by the WHO Secretariat.”

What exactly this will mean for kratom internationally and potential future reviews is unclear, but we can be certain that kratom’s enemies will try to bring it up again. In fact, one member of the committee wanted a critical review of mitragynine and 7-hydroxymitragynine.

“With respect to mitragynine and 7-hydroxymitragynine, the Committee, except for one member, also concluded that there is insufficient evidence to recommend a critical review at this time.”

More info to come!

While this information is all incredibly encouraging and exciting, the AKA is working hard to understand what the full fallout of the decision will be for kratom. We anticipate the FDA will regroup and look at other avenues to ban kratom, especially at state and local levels. The fight isn’t over, but we can’t thank you enough for your support in this victory!

Make sure you’re signed up for updates, join the American Kratom Protectors, and we will hold a full debriefing webinar soon!

Join the American Kratom Protectors